PS11 A COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT FOR THE TREATMENT OF MODERATE AND SEVERE PSORIASIS IN MEXICO
Varqes-Valencia J1, Soteló-Guzmán M2, Mouíd-Quevedo P3, Muciño-Ortega E4, Galindo-Suárez RM5, Vargas-Valencia J2
1Hemophony Consulting S. a. de C. v., Mexico City, Mexico, 2,3Fisher, New York, NY, USA, 4Fisher, Mexico City, Mexico

OBJECTIVES: Biological treatments have dramatically changed the therapeutics, outcomes and cost management of psoriasis, a common chronic disease that strongly affects quality of life of patients. The aim of this study was to assess the cost-effectiveness of biologic alternatives currently available in Mexico for treatment of moderate to severe psoriasis from an institutional perspective. METHODS: A decision-tree model was developed to simulate the clinical course of patients treated with etanercept, adalimumab, infliximab or ustekinumab as first-line therapies, as well as treatment associated costs (2-year timeframe with a 5% annual discount rate). Effectiveness measures were the proportion of patients reaching 75% improvement in the Psoriasis Area and Severity Index (PASI-75) and quality adjusted life years gained (QALY’s). Costs considered included: biologics drugs, concomitant medication, medical follow-up and side effects management. Clinical response of alternatives was extracted from published literature, while unit costs were collected from Instituto Mexicano del Seguro Social (IMSS) official databases. Probabilistic sensitivity analyses were completed. RESULTS: After two years, the proportions of patients reaching PASI-75 were 59%, 62.1%, 62.7%, and 64.5% for adalimumab, etanercept, infliximab and ustekinumab, respectively ([p=0.077, Friedman test] compared to each other at a level of p=0.05). Effectiveness was similar to adalimumab, US$562.91 (±17.8%) compared to infliximab and US$12,120.74 (±46.74%) compared to ustekinumab (the most costly alternative). CONCLUSIONS: Given that effectiveness of the biologic treatments analyzed is similar overall the time horizon used, etanercept treatment represents the less expensive alternative for the management of moderate and severe psoriasis at IMSS.

PS12 A DISCRETE EVENT SIMULATION TO OPTIMIZE THE ALLOCATION OF CONSTRAINED HOSPITAL RESOURCES FOR GLAUCOMA
Vázquez-Carrillo J1, Castano S2, Chen C3, Lee J4
1Conway Market Access Services, Inc., San Diego, CA, USA, 2Queen’s University, Kingston, ON, Canada, 3Deloitte Pty Ltd, Bruce, ACT, Australia

OBJECTIVES: A discrete event simulation that includes hospital services at the Royal Adelaide Hospital. The DES model was developed to represent the use of glaucoma services at the Royal Adelaide Hospital. The DES describes disease progression and pathways of care, where disease progression is influenced by the frequency and content of hospital visits, and where visit. Individuals, who are competing for access to hospital services, are assigned characteristics that represent relevant patient and disease characteristics. Across all individuals, these data inform the demand for services over time, which is combined with information on the supply of available resources within the system to analyze alternative approaches to the use of available resources. RESULTS: The base case model was then validated against the real-life data and clinical measures over time. Analysis of the model shows variation in the total QALYs gained by cohorts of glaucoma patients over their remaining lifetime, according to alternative treatment decision algorithms (e.g. medication versus surgical intervention), surveillance and imaging algorithms (e.g. variation in relative follow-up schedules for high and low priority patients). CONCLUSIONS: The applied framework illustrates the potential value of DES in modelling the costs and health benefits of alternative approaches to organising scarce physical resources, providing estimates of health gains that can be achieved in the absence of the introduction of new technologies.

PS13 INCREMENTAL COST-UTILITY ANALYSIS OF DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF MACULAR EDEMA FOLLOWING RETINAL VEIN OCCLUSION
Kwasiuks J1, Yeh WS1, O’Leary B2, Ackerman S3, Sharma S4, Adena M5
1Allergan, Irvine, CA, USA, 2Covance Pty Ltd, North Ryde, NSW, Australia, 3Covance Market Access Services, Inc., San Diego, CA, USA, 4Queen’s University, Kingston, ON, Canada, 5Deloitte Pty Ltd, Bruce, ACT, Australia

OBJECTIVES: Macular edema (ME) following retinal vein occlusion (RVO) is a common cause of visual loss. The goal of this study was to examine the incremental cost-effectiveness of dexamethasone implant 0.7mg (DEX) treatment versus observation for ME following central or branch RVO (CRVO or BRVO) from a US payer perspective. METHODS: An Excel-based Markov model with 1-health state based on visual acuity (VA) plus one arm was developed. Transition matrixes were derived using individual patient-level data pooled from two identical phase 3 studies. Enrolled study patients at baseline had mean age of 65 years and study-eye VA of 20/80. DEX patients were assumed to undergo up to treatments over 2 years. Forty percent of patients were assumed to receive DEX in their WSE at model entry and a time-dependent risk of fellow eye occurrence (FEO) was incorporated. Costs and outcomes were discounted at 3%. Deterministic and probabilistic sensitivity analyses were conducted. RESULTS: Reference case ICERs were $23,416 and $20,597 per QALY for BRVO and CRVO, respectively; and sensitive to the percent of patients incurring the RVO in the BSE, risk of FEO, and cost of vision loss. Probabilistic sensitivity analyses demonstrated that the ICERs fell below a threshold of $50,000 per QALY in 87% and 92% of simulations for BRVO and CRVO, respectively. CONCLUSIONS: Using a threshold of $50,000, DEX treatment compared to observation is supported as a cost-effective treatment option for ME following BRVO or CRVO.

PS14 COST-UTILITY ANALYSIS OF RANIBIZUMAB (LUCENTIS®) IN WET-AMD BASED ON REAL-LIFE DATA COLLECTED IN THE HELIOS STUDY AFTER RANIBIZUMAB REIMBURSEMENT IN BELGIUM
De Moorens S1, Geerts L1, Driesen S2, Annemans L3, Briët H4, Deruyck M4, Fese F4, Vancaeyseele T1
1UMCS Health Consulting, Vilvoorde, Belgium, 2Panacea Officialni BVBA, Brussels, Belgium, 3Client Services, University Foundation Ghent, Ghent, Belgium, 4Client Services, Ghent University and University Hospital Ghent, Belgium

OBJECTIVES: Assess cost-utility of ranibizumab (Lucentis®) in wet-AMD based on real-life evidence regarding quality of life, treatment patterns and effectiveness collected in the Belgian observational HELIOS study including 253 patients treated with ranibizumab after reimbursement approval. METHODS: An existing model, developed for clinical trial-based analyses, was extended to include a real-life ranibizumab arm. This 10-year MS-Excel Markov model with 5 visual acuity (VA) levels and 1 death state predicts VA in patients treated with ranibizumab, Visudyne® photodynamic therapy (PDT) or best supportive care (BSC). Transition probabilities and treatment frequency for ranibizumab (on average 5 injections during year 1) were provided by the HELIOS trial (1-year interim data). For comparability these data were obtained from several clinical trials (ANCHOR, MARINA, PIER and TAP). Base-case probabilities and utilities correlating with treated-eye VA were obtained from the HELIOS study. Two-year treatment duration was modelled, followed by BSC. Costs (2010) from the perspective of the health care payer (social services + patient) were obtained from literature and expert opinion. Costs (3%) and outcomes (1.5%) were discounted. Sensitivity analyses covered variability in efficacy, costs, treatment frequency and utilities. RESULTS: Vision gain in real-life was in line with published data but lower in monotherapy. Visudyne® injection frequency and costs were lower in real-life than anticipated from ranibizumab clinical trials. Base-case analyses versus BSC (MARINA, PIER and TAP) consistently revealed cost-utility of ranibizumab, with results ranging from dominance to $3,676/QALY. Base-case analyses versus PDT (PIER and TAP) suggested dominance of the real life ranibizumab arm. Results were most sensitive to the cost of blindness and time horizon, but remained generally within acceptable limits. At an acceptability threshold of 35,000/QALY, the probability that real-life ranibizumab is cost-effective ranged from 84% to 100%.

CONCLUSIONS: Real-life use of ranibizumab in wet-AMD appeared highly cost-effective compared to BSC and PDT.